J M Wheeler1, A Loukola, L A Aaltonen, N J Mortensen, W F Bodmer. 1. Cancer and Immunogenetics Laboratory, Imperial Cancer Research Fund, Institute of Molecular Medicine, John Radcliffe Hospital, Oxford, UK. wheelerj@icrf.icnet.uk
Abstract
INTRODUCTION: Hypermethylation of the promoter region of the hMLH1 gene is associated with absent expression of MLH1 protein in sporadic colorectal cancers with microsatellite instability (MSI+), and it has been proposed that methylation may be a mechanism of inactivation in Knudson's hypothesis. The incidence of hypermethylation of the hMLH1 promoter in hereditary non-polyposis colorectal cancer (HNPCC) versus MSI+ sporadic colorectal cancer was investigated and compared. METHODS: DNA was available from 10 HNPCC colorectal cancers (median age 58 years, range 39-67) with germline mutations in hMLH1 and 10 MSI+ sporadic colorectal cancers (mean age 79 years, range 41-85). MSI was determined by amplification of BAT26 and TGF-beta RII. The methylation status of the hMLH1 promoter was studied by the polymerase chain reaction (PCR) based HpaII restriction enzyme assay technique. Evidence of allelic loss at hMLH1 was searched for in the HNPCC colorectal cancers. RESULTS: All cases were confirmed to be MSI+. The promoter region of hMLH1 was hypermethylated in seven of 10 MSI+ sporadic cancers versus 0 of 10 HNPCC cancers (p<0.002). Evidence of loss of heterozygosity at hMLH1 was observed in eight of the 10 HNPCC colorectal cancers. CONCLUSION: While mutations and allelic loss are responsible for the MSI+ phenotype in HNPCC cancers, the majority of MSI+ sporadic cancers are hypermethylated in the promoter region of hMLH1. These data further support our argument that tumours from HNPCC patients, which almost always acquire a raised mutation rate, mostly follow a different pathway from MSI+ sporadic tumours.
INTRODUCTION: Hypermethylation of the promoter region of the hMLH1 gene is associated with absent expression of MLH1 protein in sporadic colorectal cancers with microsatellite instability (MSI+), and it has been proposed that methylation may be a mechanism of inactivation in Knudson's hypothesis. The incidence of hypermethylation of the hMLH1 promoter in hereditary non-polyposis colorectal cancer (HNPCC) versus MSI+ sporadic colorectal cancer was investigated and compared. METHODS: DNA was available from 10 HNPCC colorectal cancers (median age 58 years, range 39-67) with germline mutations in hMLH1 and 10 MSI+ sporadic colorectal cancers (mean age 79 years, range 41-85). MSI was determined by amplification of BAT26 and TGF-beta RII. The methylation status of the hMLH1 promoter was studied by the polymerase chain reaction (PCR) based HpaII restriction enzyme assay technique. Evidence of allelic loss at hMLH1 was searched for in the HNPCC colorectal cancers. RESULTS: All cases were confirmed to be MSI+. The promoter region of hMLH1 was hypermethylated in seven of 10 MSI+ sporadic cancers versus 0 of 10 HNPCC cancers (p<0.002). Evidence of loss of heterozygosity at hMLH1 was observed in eight of the 10 HNPCC colorectal cancers. CONCLUSION: While mutations and allelic loss are responsible for the MSI+ phenotype in HNPCC cancers, the majority of MSI+ sporadic cancers are hypermethylated in the promoter region of hMLH1. These data further support our argument that tumours from HNPCC patients, which almost always acquire a raised mutation rate, mostly follow a different pathway from MSI+ sporadic tumours.
Authors: C E Bronner; S M Baker; P T Morrison; G Warren; L G Smith; M K Lescoe; M Kane; C Earabino; J Lipford; A Lindblom Journal: Nature Date: 1994-03-17 Impact factor: 49.962
Authors: N Papadopoulos; N C Nicolaides; Y F Wei; S M Ruben; K C Carter; C A Rosen; W A Haseltine; R D Fleischmann; C M Fraser; M D Adams Journal: Science Date: 1994-03-18 Impact factor: 47.728
Authors: L A Aaltonen; P Peltomäki; F S Leach; P Sistonen; L Pylkkänen; J P Mecklin; H Järvinen; S M Powell; J Jen; S R Hamilton Journal: Science Date: 1993-05-07 Impact factor: 47.728
Authors: J M Cunningham; E R Christensen; D J Tester; C Y Kim; P C Roche; L J Burgart; S N Thibodeau Journal: Cancer Res Date: 1998-08-01 Impact factor: 12.701
Authors: J Young; B Leggett; C Gustafson; M Ward; J Searle; L Thomas; R Buttenshaw; G Chenevix-Trench Journal: Hum Mutat Date: 1993 Impact factor: 4.878
Authors: F S Leach; N C Nicolaides; N Papadopoulos; B Liu; J Jen; R Parsons; P Peltomäki; P Sistonen; L A Aaltonen; M Nyström-Lahti Journal: Cell Date: 1993-12-17 Impact factor: 41.582
Authors: N C Nicolaides; N Papadopoulos; B Liu; Y F Wei; K C Carter; S M Ruben; C A Rosen; W A Haseltine; R D Fleischmann; C M Fraser Journal: Nature Date: 1994-09-01 Impact factor: 49.962
Authors: Lars Henrik Jensen; Anders Aamann Rasmussen; Lene Byriel; Hidekazu Kuramochi; Dorthe Gylling Crüger; Jan Lindebjerg; Peter V Danenberg; Anders Jakobsen; Kathleen Danenberg Journal: Cell Oncol (Dordr) Date: 2013-09-12 Impact factor: 6.730
Authors: Lars Henrik Jensen; Hidekazu Kuramochi; Dorthe Gylling Crüger; Jan Lindebjerg; Steen Kolvraa; Peter Danenberg; Kathleen Danenberg; Anders Jakobsen Journal: Tumour Biol Date: 2011-07-06
Authors: M Spaepen; B Vankeirsbilck; S Van Opstal; S Tejpar; E Van Cutsem; K Geboes; E Legius; G Matthijs Journal: Fam Cancer Date: 2006 Impact factor: 2.375
Authors: A McGivern; C V A Wynter; V L J Whitehall; T Kambara; K J Spring; M D Walsh; M A Barker; S Arnold; L A Simms; B A Leggett; J Young; J R Jass Journal: Fam Cancer Date: 2004 Impact factor: 2.375